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Objective. Systemic sclerosis (SSc) is a rare, heterogeneous disease, which affects different organs and therefore requires interdis-
ciplinary diagnostic and therapeutic management. To improve the detection and follow-up of patients presenting with different disease
manifestations, an interdisciplinary registry was founded with contributions from different subspecialties involved in the care of patients
with SSc.
Methods. A questionnaire was developed to collect a core set of clinical data to determine the current disease status. Patients were
grouped into five descriptive disease subsets, i.e. lcSSc, dcSSc, SSc sine scleroderma, overlap-syndrome and UCTD with scleroderma
features.
Results. Of the 1483 patients, 45.5% of patients had lcSSc and 32.7% dcSSc. Overlap syndrome was diagnosed in 10.9% of patients, while
8.8% had an undifferentiated form. SSc sine scleroderma was present in 1.5% of patients. Organ involvement was markedly different
between subsets; pulmonary fibrosis for instance was significantly more frequent in dcSSc (56.1%) than in overlap syndrome (30.6%) or
lcSSc (20.8%). Pulmonary hypertension was more common in dcSSc (18.5%) compared with lcSSc (14.9%), overlap syndrome (8.2%) and
undifferentiated disease (4.1%). Musculoskeletal involvement was typical for overlap syndromes (67.6%). A family history of rheumatic
disease was reported in 17.2% of patients and was associated with early disease onset (P<0.005).
Conclusion. In this nationwide register, a descriptive classification of patients with disease manifestations characteristic of SSc in five groups
allows to include a broader spectrum of patients with features of SSc.
KEY WORDS: Systemic sclerosis, Scleroderma, Connective tissue disease, Overlap syndrome, Undifferentiated disease.
Introduction
Systemic sclerosis (SSc) is a rare, multisystem disease showing a
large individual variability in the extent of skin and organ
involvement as well as in disease progression and prognosis. SSc is
predominantly a female-oriented disease with reported female
to male ratios between 3:1 and 6:1, most likely influenced by
ethnical and regional factors [1–6]. The annual incidence was
estimated to range between 0.6 and 19 cases per million
populations, depending on methodological differences in case
definition and ascertainment, the time period, different genetic
and ethnic backgrounds. Accordingly, reported prevalence rates
were reported between 4 and 242 cases per million populations
[5, 7–11]. It has also been reported that SSc occurs significantly
more frequent in families with SSc than in the general population.
As of yet, the strongest risk factor identified for SSc is a positive
family history of SSc. However, the absolute risk for each family
member remains rather low (<1%) [12]. SSc is associated with a
markedly increased mortality, depending on racial differences,
presence and severity of internal organ involvement, age at
diagnosis and gender [5]. Thus, the reported 5yr survival rates
vary considerable between 50% and 80% [8, 13].
In 1980, the ACR published preliminary classification criteria
showing a 97% sensitivity and 98% specificity for SSc to classify
patients with established disease [14]. During recent years, a
descriptive sub-classification of lcSSc vs dcSSc, based on a number
of clinical characteristics elaborated by Le Roy et al. [15], has been
widely accepted and used in clinical practice. However, none of
these classifications are satisfactory for daily clinical practice. For
instance, a subset of patients presents with virtually no
scleroderma, but has RP, pulmonary hypertension or other
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associated autoantibodies. This subset has been described as SSc
(scleroderma) sine scleroderma [16, 17]. Also, a significant number
of patients belong to a subgroup with symptoms of SSc occurring
simultaneously with those of other CTDs like myositis, SS or
lupus erythematodes. These patients are often classified as
scleroderma overlap syndrome and are characterized by typical
autoantibodies, e.g. most frequently anti-U1-RNP- or anti-PmScl-
antibodies [18]. Furthermore, due to improved health care
and activity of patients’ associations, patients present earlier
in the course of the disease with symptoms suggestive of, but
not conclusive for a diagnosis of definite SSc, e.g. RP and
scleroderma-specific ANAs; these symptoms have been described
as UCTD [19, 20].
To date, there exist no data on the occurrence of these
additional disease subsets in a large population. In order to
improve clinical care and to develop recommendations for the
diagnosis and treatment of SSc, the German Network for
Systemic Scleroderma (DNSS) was established in October 2003,
funded by the German Federal Ministry of Education and
Research (BMBF). A core activity of this network is a patient
registry that comprises centres in all parts of Germany as well as
one centre in Graz (Austria). A major goal of the network was to
ensure acquisition of patients with different disease presentations
and clinical variants of this heterogenous disease. This goal was
not only facilitated by a country-wide network, but also by
cooperation of different subspecialties being primarily involved in
the care of patients with SSc in Germany, i.e. rheumatologists,
dermatologists, pulmonologists and nephrologists.
This report is a large cross-sectional analysis of SSc disease
subsets extending over the classification of Le Roy on a
nationwide basis. The data presented herein strongly indicate
that an improved classification is needed. Together with interna-
tional registries such as EULAR Scleroderma Trials and Research
(EUSTAR) [21], the data form a basis for clinical trials and
evidence-based recommendations for diagnosis and therapy.
Patients and methods
The DNSS was founded in October 2003 on a grant by the
BMBF. The network is based on different subspecialties consist-
ing of dermatologists, rheumatologists, pulmonologists and
nephrologists from altogether 27 centres. Among these, 10 are
rheumatological centres (Aachen, Bad Bramstedt, Baden-Baden,
Bad Nauheim, Berlin, Freiburg, Hamburg, Heidelberg,
Regensburg and Treuenbrietzen), 12 are dermatological centres
(Berlin, Dresden, Go ¨ ttingen, Cologne, Mainz, Minden, Munich,
Mu ¨ nster, Regensburg, Ulm, Wuppertal and Wu ¨ rzburg) and in
two centres the Departments of Dermatology and Rheumatology
jointly register their patients (Du ¨ sseldorf and Tu ¨ bingen). In
addition, a pulmonary centre each in Giessen and Graz, and a
nephrological centre in Cologne-Merheim took part, adding their
expertise with regard to the specific complications of pulmonary
or renal involvement of SSc.
The ethics committee of the coordinating centre, i.e. the
Cologne University Hospital, gave a positive vote on a patient
information and consent form for the registry. On the basis of this
document, informed patient consent as well as the approval of the
local ethics committees in all participating centres was obtained
prior to registering patients. By April 2007, more than 1483 SSc
patients had been registered.
In 2003, a disease- and organ-specific questionnaire was
designed with the consent of all network members, including
information on gender, date of birth, height, weight, family
history for inflammatory rheumatic disease signs and symptoms
of organ involvement of skin, heart, lung, gastrointestinal tract,
kidney, musculoskeletal system, nervous system and characteristic
laboratory data such as ANA.
Two reference documents were prepared to ensure consistency
of registered patients’ data in the network centres. These
documents included definitions of questionnaire items and
recommendations for diagnostic procedures.
Organ involvement was defined as follows: RP was character-
ized by recurrent spasms of small digital arterioles/arteries at
fingers and toes, usually triggered by cold and emotional stress.
Clinically a sudden pallor of individual digits was followed by
reactive hyperaemia, in severe cases also by cyanosis [22]. Age at
RP onset was considered to be the age at which this symptom
appears. We defined the first non-RP onset as the time/age when
the first skin changes (puffy fingers, sclerodactily, truncal
scleroderma) developed and the second non-RP onset as the
time/age at which first organ lesions occurred. All registered
patients were asked for the date/age when RP, skin changes and
organ manifestations were noticed/diagnosed.
Skin involvement was evaluated using the Rodnan skin
score that assesses the skin thickness by clinical palpation of 17
body areas on a scale of 0–3 [23, 24]. Thickening and fibrosis of
the skin as one of the first recognized phenomenon in SSc still
forms the basis of most classification criteria and proposed subsets
of the disease [15, 25, 26]. With respect to these symptoms the
participants of the centres were trained several times by meetings
of the network or EUSTAR-organized Rodnan skin score courses
(Budapest, January 2005; Bad Nauheim, January 2007) to ensure
standardized and correct performance of skin scoring within the
network.
Digital tip ischaemia was associated with digital pitting scars,
ulcerations or gangrene, or both.
Pulmonary manifestation was established, when pulmonary
interstitial fibrosis and/or isolated pulmonary hypertension were
found. Isolated pulmonary hypertension was defined as clinical
evidence of right heart failure and/or increased mean pulmonary
arterial pressure (PAPm >25mmHg at rest or PAPm >30mmHg
during exercise) as determined by right heart catheterization. In
addition, an estimated right ventricular systolic pressure (RVSP)
>40mmHg as determined by echocardiography was used to
define likely PAH. Patients with dyspnoea [New York Heart
Association (NYHA) Grade II and upwards] show often isolated
impairments of carbon monoxide transfer factor (TLCO) with
<75% of the predictive values with the forced vital capacity
<80%. Pulmonary interstitial fibrosis was defined as SSc
associated, when other possible causes of lung fibrosis were
excluded and bilateral fibrosis confirmed by chest X-ray, high-
resolution CT scan and/or restrictive pulmonary abnormalities on
pulmonary function tests (TLC <80%) were found.
Gastrointestinal involvement was defined as gastrointestinal
motility disturbance, dysphagia, nausea, malabsorption, oesopha-
geal stenosis, gastro-oesophageal reflux or intestinal pseudo-
obstruction. Oesophageal dysphagia and reflux were suggested by
subjective symptoms like not able to swallow liquid or hard food
as well as intermittent heart burn and by the oesophageal
manometric examination and gastroscopy.
Kidney involvement was defined as the presence of renal
insufficiency encompassing renal insufficiency due to acute renal
crisis (age-related creatinine clearance <80ml/min). For the
diagnosis of proteinuria we used a urine microelectrophoresis
that indicated very early disturbances in the renal filter function
(albuminuria 30mg/24h or 20mg/l; proteinuria 300mg/24h
or 200mg/l).
Cardiac disease was defined as one of the following: palpita-
tions, conduction disturbance and diastolic dysfunction on the
echocardiogram.
Skeletal muscle disease was defined as proximal muscle
weakness or atrophy recorded on clinical evaluation and raised
serum muscle enzyme levels. The item musculoskeletal system
(Table 2) summarizes musculoskeletal involvement (with muscle
weakness, atrophia and CK elevation) as well as articular
involvement (with synovitis, joint contractures).
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with or without tenderness to palpation, in one or more joints. We
also recorded any kind of joint contracture (limitation in active as
well as passive movements) or tendon friction rubs. Nervous
system involvement was defined as trigeminal neuralgia, carpal
tunnel syndrome or polyneuropathy. Sicca symptoms were defined
as decreased secretion of one or more adenoids and the masticatory
organ was characterized by microstomia, defined as obvious
decreased mouth opening clearly detected by the investigators due
to the disease and/or fibrosis of the lingual frenulum.
To ensure the detection of disease heterogeneity, the registry
defined additional distinct subsets apart from lcSSc and dcSSc, i.e.
overlap syndrome, UCTD with features of scleroderma and SSc
sine scleroderma.
The dcSSc was defined as a progressive form with an early
onset of RP, usually within 1yr of onset of skin changes. This
subset is characterized by rapid involvement of trunk, face,
proximal and distal extremities. Very frequently, anti-Scl 70 (anti-
topoisomerase-I) antibodies are present [15].
The lcSSc was defined by skin affection of the extremities distal
to the knee and elbow joints, facial skin and occurrence of RP.
These patients often (50–70%) have ACAs [15].
Overlap syndrome was defined as a disease occurring with
clinical aspects of SSc (according to the ACR criteria) or main
symptoms of SSc simultaneously with those of other CTDs/other
autoimmune diseases such as dermatomyositis, SS or lupus
erythematodes. These patients are mostly positive for anti-
U1-RNP- or anti-PmScl-antibodies [18].
Sclerosis (scleroderma)sinescleroderma was defined bya positive
RP, no skin alterations, pulmonary arterial hypertension (PAH),
cardiac, pulmonary and gastrointestinal involvement [16, 17, 26].
Undifferentiated SSc was defined as positive RP (at least
bicolour) and at least one further feature of SSc (typical nail-fold
capillary alterations, puffy fingers, pulmonary hypertension) and/
or detectable scleroderma-specific autoantibodies without ful-
filling the ACR criteria for SSc [19, 20].
Data recording and statistical analyses
The DNSS maintains a centralized online patient registry that
includes all SSc-patient data in a standardized four-page DNSS
questionnaire. The Central Office for Coordination (CoC) was set
up at the Department of Dermatology and Venerology at the
University of Cologne and acts as data manager. The DNSS
cooperates closely with the Cologne Center for Clinical Studies
(KKSK) that developed a DNSS online patient registry using the
MACRO software for Clinical Trials (Infermed Ltd., London).
Seven clinical centres currently use the option to register their
patients online. The remaining centres perform their registrations
on paper and send the filled-in questionnaires to the central office
for coordination, where the registration forms are validated and
entered into the online registry.
The analysis is a cross-sectional study. The data were
statistically analysed using Microsoft Office Excel 2003 and
SPSS 14.0 for Windows for tabular and graphic representation.
Statistical evaluation was performed using contingency table tests
( 
2-test or Fisher’s exact t-test) to describe significant differences
or associations. When multiple tests were performed, only
P-values <0.0001 are mentioned. Bivariate analysis was per-
formed for comparison of subtypes. For most data sets, <2% of
data were missing (Table 2). However, in some sets the percentage
of missing data is higher, e.g. family case history, masticatory
organ, DLCO. This is largely due to the fact that these parameters
were added to the questionnaire after the registry was initiated.
Results
As of February 2007, a total of 1483 patients had been enrolled
in the registry. The female to male ratio was 5:1. The mean
age was 55.713.7yrs (S.D.). On average, female patients
56.113.9yrs were older than male 53.912.4yrs patients. A
family history of rheumatic diseases was reported by 17.2% of all
patients (Table 1) and was significantly associated with a lower
mean age and earlier disease onset of RP, skin involvement and
internal organ involvement (Fig. 1).
A detailed analysis of age at disease onset, skin and organ
involvement for the different disease subsets is shown in Table 1.
Disease presentation in different subsets
The frequency of the disease subsets is shown in Table 2. The most
frequent subset was the limited cutaneous form (45.5%), followed
by the diffuse cutaneous type (32.7%), overlap syndrome (10.9%)
and undifferentiated form (8.8%). SSc sine scleroderma was
found in 1.5% of all registered patients. The description of skin
involvement in patients characterized as sclerosis sine scleroderma
represents the presence of puffy fingers and not sclerodactily.
However, due to the low frequency in the registry, this subset was
excluded from further statistical analysis. The female to male ratio
ranged from 3.2:1 in dcSSc to 7.2:1 in lcSSc and was around 5:1
in overlap syndrome and the undifferentiated subset.
The time interval between the onset of the RP and skin and
internal organ involvement varied significantly between disease
subsets (Fig. 2), being shortest for the dcSSc variant and longest
for the lcSSc disease variant. On average, skin involvement
preceded internal organ involvement in all subsets.
Organ involvement for the different disease subsets is shown
in Fig. 3. Here, the dcSSc subset shows the highest frequencies
for pulmonary fibrosis, pulmonary hypertension, kidney and
heart involvement. Kidney involvement was more common in
the diffuse subset (P<0.001), but did not reach the level of
significance (P<0.0001). Clinically prominent symptoms as
digital ulcers, joint contractures, proteinuria, conduction blocks
and restrictive pulmonary function were also most frequent in the
dcSSc subset. In contrast, gastrointestinal involvement did not
show significant differences between the subsets of dcSSc, lcSSc
and overlap syndrome.
Pulmonary fibrosis had a frequency of 56.1% in dcSSc
compared with 30.6% in overlap syndrome and 20.8% in lcSSc.
Pulmonary hypertension was also most frequent with 18.5% in
TABLE 1. Distribution of age, onset of organ involvement and disease subsets
Age (yrs) Age at RP onset (yrs) Age at skin involvement (yrs) Age at organ involvement (yrs)
Total 55.7 13.7 44.3 15.6 47.9 14.4 50.3 14.2
Family case history 53.7 13.0 41.5 15.4 46.1 14.0 47.9 13.6
Female 56.0 13.9 44.2 15.8 48.1 14.6 50.5 14.5
Male 53.9 12.4 45.1 14.6 47.0 13.4 49.1 12.4
Overlap-S. 50.9 13.5 40.5 15.7 43.6 15.5 45.0 14.6
Undiff. Scl. 54.7 12.5 46.8 14.6 49.6 12.5 50.9 13.3
Scl. sine Scl. 54.1 15.8 42.7 14.9 48.1 14.3 48.2 16.0
dcssc 54.1 14.1 44.5 15.2 46.4 14.3 48.6 14.3
lcSSc 58.5 12.7 44.7 15.8 49.9 14.0 52.2 13.7
Values expressed as mean S.D. Overlap-S: Overlap syndrome; Undiff. Scl: Undifferentiated scleroderma; Scl. sine Scl.: sclerosis (scleroderma) sine scleroderma; dcSSc: diffuse cutaneous
systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis.
German Network for Systemic Scleroderma 1187TABLE 2. Patient characteristics
Total Missing data lcSSc dcSSc Overlap-S. Undiff. Scl. Scl. sine Scl.
Number of patients, n (%) 1483 (100) 0 (0) 674 (45.5) 484 (32.7) 162 (10.9) 130 (8.8) 22 (1.5)
Female 83.4 0.2 87.8 76.1 84.2 84.3 90.9
Male 16.4 0.2 12.2 23.9 15.8 15.7 9.1
Family case history 17.2 19.8 20.2 23.5 25.8 24.1 18.8
ANA positive 90.4 1 92.9 93.9 95.2 83.5 95
Scl 70 positive 27.6 1.2 16.2 55.8 15.1 10.7 40
ACA positive 36.4 1 61.5 11.2 16.4 34.7 35
SSc-associated antibodies 32.5 1 27.6 31.6 68.5 35.5 30
Elevated acute-phase reactants (>30mm/h) 15.9 16.3 13.4 17.8 14.8 17.7 4.5
Percentage of organ involvement by SSc subsets
RP 94.4 0.1 96.3 94.2 95.9 89.3 95.5
Skin involvement 87.8 0.3 91.5 97.6 82.3 60 63.6
PAH 15.8 0.1 14.9 18.5 8.2 4.1 13.6
Pulmonary fibrosis 34.5 0.1 20.8 56.1 30.6 18.2 59.1
Oesophagus 60 0.1 59.2 69.3 61.2 35.5 72.7
Stomach 14.2 0.2 15.3 15.6 14.3 8.3 27.3
Intestine 5.7 0.2 6.1 5.3 5.4 7.4 18.2
Kidney 10.5 0.2 9.1 15.9 6.1 8.3 22.7
Heart 14.6 0.2 12 23 10.2 8.3 13.6
Musculoskeletal system 47.5 1.4 44.9 56.6 67.6 44.6 45.5
Nervous system 6.4 2.2 4.1 7.1 10.3 6.6 4.5
Sicca-symptoms 39.5 2.5 43.5 39.7 38.9 43.3 45.5
Masticatory organ 24.1 7.2 23.7 34.1 24.4 18.5 15
Percentage of present symptoms by SSc subsets
Digital ulcers 24.4 2.2 23.8 34.4 21.2 9.9 33.3
Synovitis 15.1 3.4 11.7 19.2 22.7 14.9 33.3
Joint contractures 26.1 3 22.6 39.7 21.8 15.7 22.2
Tendon friction rubs 8.3 3.2 6.6 13.1 9.9 8.3 27.8
CK elevation 9.2 2.8 5.5 12.1 22.8 6.7 11.1
Muscle weakness 27.7 2 24.7 33.5 40.4 22.3 33.3
Muscle atrophy 16.9 3 14.3 21.4 25.4 9.1 16.7
Dysphagia, reflux 60.4 1.9 60.8 69.2 63 43 61.1
Satiety, nausea 16.5 3.6 17.9 16.4 20.6 19.8 33.3
Diarrhoea, constipation 24.2 3.6 27.2 25.2 22.1 32.2 35.3
Hypertension 24 2.2 28.2 24.5 19.9 29.8 38.9
Renal insufficiency 13.7 2.6 16.5 15.6 8.3 8.3 22.2
Proteinuria 9.5 3.1 8.9 15.2 9.7 6.7 11.1
Dyspnoea 31.2 2 32 40.4 23.3 18.2 50
Palpitations 22.3 2.8 23.1 20.1 21.5 23.1 27.8
Conduction block 12.9 2.6 10.8 19.2 10.3 8.3 16.7
Diastolic dysfunction 14.1 3.4 14.9 19 9.1 8.3 17.6
Lung restrictive disease 23.7 2.8 16.1 40.7 18.6 10 33.3
Polyneuropathy 8 4.9 6.8 8 8.8 5.9 0
Trigeminal neuralgia 1.6 4.7 1.1 2.6 1.5 1.7 0
DLCO ( 75% 24.8 51.9 23.6 31.4 21 10.8 9.1
mRSS (mean  S.D.) 9.2 9.2 13.1 6.9 6.2 15.2 10.9 6.9 7.9 2.7 4.3 0.6 0.8
FIG. 1. Mean ages of RP onset and organ involvement by family history.
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syndrome. A finding of interest was a substantial proportion of
patients with isolated pulmonary hypertension without lung
fibrosis both in the dcSSc and lcSSc subsets (27.7% vs 60%;
P<0.001).
Digital ulcers were reported most frequently in the dcSSc subset
(34.4%), but also to a significant degree in overlap syndrome
patients (21.2%). Oral involvement was reported in 34.1% of
patients with dcSSc and in 23.7% of patients with lcSSc.
Involvement of the nervous system presenting as polyneuropathy
was reported in 6–8% of patients with no difference between
subsets. Trigeminal neuralgia was reported in percentages around
1–3% for all subsets.
Musculoskeletal symptoms were most prominent in patients
with overlap syndrome, with signs such as CK elevation and
synovitis being more frequent when compared with other subsets
(P<0.0001). CK elevation was reported significantly more often
in 22.8% of overlap syndrome patients compared with 12.1% in
the dcSSc subset and 5.5% in the lcSSc subset (P<0.0001),
respectively.
Differences between medical subspecialties
Different disease characteristics and different disease subsets may
determine which specialist provides primary care to the patient,
e.g. rheumatologist or dermatologist. Interestingly, regarding the
four major subsets a significant difference in subset frequency was
only found for the overlap syndrome. Overlap syndrome, which is
usually characterized by prominent musculoskeletal involvement,
was more frequently diagnosed in rheumatological centres
FIG. 2. Mean time interval between RP onset and organ involvement by disease.
FIG. 3. Relative frequency of organ involvement by different subsets.
German Network for Systemic Scleroderma 1189(P<0.01). The frequency of dcSSc and lcSSc in the two specialties
showed no significant difference.
Results of the analysis of organ involvement and symptoms of
patients presenting to rheumatological or dermatological clinics
are shown in Fig. 4. Symptoms indicating prominent involvement
of the musculoskeletal system (including joint contractures,
synovitis, muscle weakness and atrophy) were more prevalent in
rheumatological centres (P<0.001). This was also found for
subjective symptoms such as sicca complaints, palpitations and
signs such as diastolic dysfunction or arterial hypertension.
Digital ulcers were equally prevalent in dermatological vs
rheumatological centres (25.5% vs 23.8%; P<0.05).
In contrast, pulmonary fibrosis, pulmonary hypertension,
conduction blocks or digital ulcers were equally prevalent in
rheumatological and dermatological centres.
Discussion
SSc is characterized by a remarkable disease heterogeneity in
organ involvement, severity and prognosis. The 1980 ACR criteria
were established to classify patients with definite disease. In
clinical practice, the classification of lcSSc vs dcSSc [15] is
nowadays widely used. However, a significant number of patients
belongs to subgroups, which do not fit into this classification,
e.g. who are presenting with symptoms of SSc occurring
simultaneously with symptoms of other CTDs such as myositis,
SS or lupus erythematodes. These patients have been classified as
scleroderma overlap syndrome being characterized by typical
autoantibodies, e.g. detectable anti-U1-RNP- or anti-PmScl-
antibodies [18], although the usefulness of this category is
controversial. Also, due to improved health care, patients present
early in the disease course with symptoms suggestive but not yet
sufficient to diagnose definite SSc (e.g. RP and scleroderma-
specific ANA).
In SSc, as in other rare diseases, large registries are a
prerequisite to identify more uniform cohorts of patients to be
able to recruit patients into clinical studies with comparable
criteria for outcome measurement. Nevertheless, previous studies
also suggested that, even with standardized definitions in larger
registries, there may be considerable heterogeneity in patient
samples reflecting, e.g. genetic and ethnic heterogeneity, the
profile of centres with a propensity of referral cases or less-severe
community cases. Therefore, in an attempt to reduce the referral
bias, this network tried to broaden the clinical scope of the
patients being registered by relying on several medical subspecial-
ties, i.e. rheumatological, dermatological, pulmonary and nephro-
logical centres with a long-standing expertise in the care of SSc
patients.
Depending on the study, the percentage of SSc patients with the
diffuse type of the disease varies considerably (33.8% [9]; 17%
[26]; 44.6% [27]; 36.9% [21]) with the percentage of this study
(32.7%) being well within this range. The observed variation may
be partly due to regional differences in the patient population, as
e.g. Afro-American individuals have been found to suffer from the
diffuse disease type more frequently than a Caucasian population
as in this study. The lower percentage in our study can also be
attributed to the fact that this study considers more subsets,
distinguishing not only between the limited and diffuse type of the
disease but also between overlap syndromes and undifferentiated
disease. Accordingly, the limited disease variant was found in
45.5%, which is lower when compared with previous studies of
e.g. 57.5% in Walker et al. [21] or 55.8% in Ferri et al. [28]. In our
study, patients not fitting into the categories of Le Roy et al. [15]
were classified into three additional subsets. Here, we can show
that 10.9% of patients belonged to the overlap syndrome subtype
and 8.8% of patients to the undifferentiated subset, indicating
that in clinical practice a considerable number of patients
(i.e. 20%) present with clinical symptoms that are not fully
compatible with the definition of Le Roy (1988) for the limited
and diffuse cutaneous subset. The patients with overlap syndrome
can certainly be included into the Le Roy categories; however,
they clearly have a different course of the disease. Thereby, in the
present study, we have made the attempt to use the cohort
available to test the hypothesis, whether these patients could
represent a distinct subset. The data of this cohort indicate
that the clinical presentation is different and the subset appears
to influence the choice of the care provider (i.e. patients
with overlap syndrome were predominantly taken care by
rheumatologists) as well as the therapeutic approach
(Hunzelmann et al., 2008, unpublished observation). The data of
this cohort therefore support the view to consider overlap
syndrome as a distinct entity.
The average age of disease onset (defined as onset of RP) of
about 44.3yrs was similar to the value described previously in the
EUSTAR cohort [21]. Notably, a family history of rheumatic
diseases was significantly associated with a lower mean age and
FIG. 4. Relative frequency of organ involvement of SSc patients in dermatological and rheumatological centres.
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organ involvement, underlining the potential role of common
genetic traits in the pathophysiology of rheumatic diseases.
However, a comparison with other studies is difficult due to
variations in the definition of diagnosis and disease onset. The
female to male ratio of 5.08 is in the range of previous reports (7.4
[28]; 3.2 [9]). The values for involvement of the kidney (10.5%),
the heart (14.6%), the lung (34.5%) and the oesophagus (60%) in
this report are also within the range of previous data [9, 21, 27,
28]; however, marked differences could be elucidated between
disease subsets.
The detection frequency of anti-topoisomerase (27.6%) auto-
antibodies corresponds well with previous data in the study of
Ioannidis et al. [27] (25.3%) but is less than that reported in the
EUSTAR registry (40%). This study also confirms the results of
Walker et al. [21], which indicates that, to a significant degree
(28.6%), pulmonary hypertension may occur in the diffuse subset
without pulmonary fibrosis, underlining the necessity to screen for
pulmonary hypertension irrespective of the subset.
Patients with the subset of scleroderma sine scleroderma
were described in 1.5% of registered patients. However, these
patients had similar characteristics than the limited subtype and
not a specific antibody profile i.e. a preponderance of ACAs.
Nevertheless, our study supports the results of Poormoghim et al.
[16], which concluded that this subset is a clinical variant of
the limited subtype and should not be considered a distinct
disorder.
Oral involvement characterized by decreased mouth opening
and resulting in poor dental status was reported in 34.1% of
dcSSc patients indicating an important, to date underrated
contribution to disease-associated morbidity and a need for
specialized care. Trigeminal neuralgia, which has been reported to
be associated with the dcSSc subset [15], appeared at a low
frequency but markedly higher than that in the general population
(0.1/1000).
SSc is a multisystem disease and a number of subspecialties
are involved in the care of SSc patients. Care for these patients
differs from country to country, depending on the history as
well as the financial and organizational structure of the health care
system. In Germany, rheumatologists and dermatologists have
traditionally taken care of SSc patients. It can be hypothesized
that this registry, in contrast to registries established by
rheumatologists, may therefore include more patients with mild
disease, as patients with limited organ involvement (e.g. RP,
acrosclerosis) may first be seen by a dermatologist. Indeed, the
data of the registry show a trend to less severe organ involvement
in patients presenting in dermatological centres, whereas rheuma-
tological centres are more often seeing patients with overlap
syndromes. This result is supported by the data of the registry
demonstrating that patients with prominent musculoskeletal
symptoms and gastrointestinal involvement are more common
in rheumatological centres. Interestingly, patients had similar lung
involvement regarding fibrosis and pulmonary hypertension in
dermatological and rheumatological centres, which might reflect
the relatively good correlation of skin fibrosis with the extent of
lung fibrosis [29].
Comparing the data of this registry with recently published
data of the pan-European EUSTAR registry, it is apparent that
patients in this nationwide registry on average are less severely
affected by the disease and on average have a longer disease
duration, also in comparison with previous studies. Although
ethnic differences cannot be totally excluded, this presumably
reflects more efficient and better recruitment of less severely
affected patients.
This cross-sectional nationwide analysis of SSc patients
demonstrates that a sizeable number of patients belongs to
subsets other than the limited and diffuse cutaneous form of SSc.
Continuous analysis of a growing body of data will provide
substantial information for improvement of disease classification
assessment of prognosis in the different subsets and the develop-
ment of evidence-based recommendations for diagnosis and
treatment.
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